Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Parkinson disease

ADAGIO trial hints that rasagiline slows disease progression

Nature Reviews Neurology volume 6, pages 126–128 (2010)Cite this article

Subjects

The results of the ADAGIO trial, combined with those of the TEMPO trial and a large body of additional clinical and preclinical data, indicate that the possibility of treatment with rasagiline should be discussed with all patients with early Parkinson disease.

Parkinson disease (PD) is a complex neurodegenerative disease, the clinical manifestations of which include motor impairments and nonmotor components. For most patients in the early to intermediate phases of the disease, when motor impairments predominate, the currently available treatments are satisfactory overall.1 Treatment challenges emerge when disability is determined by impairments that are unresponsive to dopaminergic treatments, which include all the nonmotor impairments, together with postural instability and gait difficulties. Given these important insufficiencies of the available therapeutic interventions, the quest is on to find alternative, disease-modifying interventions that could halt or slow the disease process.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Rascol, O., Goetz, C., Koller, W., Poewe, W. & Sampaio, C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359, 1589–1598 (2002).

    Article  Google Scholar 

  2. Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).

    CAS  Article  Google Scholar 

  3. Macleod, A. D., Counsell, C. E., Ives, N. & Stowe, R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD004898. doi:10.1002/14651858.CD004898.pub2 (2005).

  4. Mandel, S., Weinreb, O., Amit, T. & Youdim, M. B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379–387 (2005).

    CAS  Article  Google Scholar 

  5. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566 (2004).

  6. Hauser, R. A. et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 24, 564–573 (2009).

    Article  Google Scholar 

  7. Marek, K., Jennings, D., Tamagnan, G. & Seibyl, J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 64 (Suppl. 2), S111–S121 (2008).

    PubMed  Google Scholar 

  8. Leber, P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 5), S10–S21 (1997).

    PubMed  Google Scholar 

  9. D'Agostino, R. B. The delayed-start study design. N. Engl. J. Med. 361, 1304–1306 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Edifício do Hospital de Santa Maria, Piso 3, Elevador 11, Lisbon, 1600, Portugal

    Cristina Sampaio & Joaquim J. Ferreira

Authors
  1. Cristina Sampaio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquim J. Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Sampaio.

Ethics declarations

Competing interests

J. J. Ferreira has acted as a consultant for and received honoraria and research support from Lundbeck and Teva Pharmaceuticals. C. Sampaio declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sampaio, C., Ferreira, J. ADAGIO trial hints that rasagiline slows disease progression. Nat Rev Neurol 6, 126–128 (2010). https://doi.org/10.1038/nrneurol.2010.2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.2

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing